T
Tucker Ezell
Researcher at Novartis
Publications - 13
Citations - 521
Tucker Ezell is an academic researcher from Novartis. The author has contributed to research in topics: Chimeric antigen receptor & Immunotherapy. The author has an hindex of 4, co-authored 10 publications receiving 425 citations.
Papers
More filters
Journal ArticleDOI
Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
Laura A. Johnson,John Scholler,Takayuki Ohkuri,Akemi Kosaka,Prachi R. Patel,Shannon E. McGettigan,Arben Nace,Tzvete Dentchev,Pramod Thekkat,Andreas Loew,Alina C. Boesteanu,Alexandria P. Cogdill,Taylor Chen,Joseph A. Fraietta,Christopher C. Kloss,Avery D. Posey,Boris Engels,Reshma Singh,Tucker Ezell,Neeraja Idamakanti,Melissa Ramones,Na Li,Li Zhou,Gabriela Plesa,John T. Seykora,Hideho Okada,Carl H. June,Jennifer Brogdon,Marcela V. Maus +28 more
TL;DR: A low-affinity single-chain variable fragment was specific for EGFRvIII over wild-type EGFR and CAR T cells transduced with this fragment were able to target antigen-expressing cells in vitro and in vivo in multiple mouse xenograft models of human glioblastoma.
Journal ArticleDOI
Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.
Dexiu Bu,Reshma Singh,Eugene E. Choi,Marco Ruella,Selene Nunez-Cruz,Keith Mansfield,Paul Bennett,Nathaniel S. Barton,Qilong Wu,Jiquan Zhang,Yongqiang Wang,Lai Wei,Shawn Cogan,Tucker Ezell,Shree Joshi,Kellie J. Latimer,Brian Granda,William R. Tschantz,Regina M. Young,Heather Huet,Celeste Richardson,Michael C. Milone +21 more
TL;DR: It is demonstrated that BCMA is prevalently, but variably expressed by all MM with expression on 25–100% of malignant plasma cells.
Journal ArticleDOI
Long-acting protein drugs for the treatment of ocular diseases.
Joy Ghosh,Andrew Anh Nguyen,Chad E Bigelow,Stephen Poor,Yubin Qiu,Nalini Rangaswamy,Richard Ornberg,Brittany Jackson,Howard H. Mak,Tucker Ezell,Vania Kenanova,Elisa de la Cruz,Ana Carrion,Bijan Etemad-Gilbertson,Roxana Garcia Caro,Kan Zhu,Vinney George,Jirong Bai,Radhika Sharma-Nahar,Siyuan Shen,Yiqin Wang,Kulandayan K. Subramanian,Elizabeth Fassbender,Michael Maker,Shawn Hanks,Joanna Vrouvlianis,Barrett Leehy,Debby Long,Melissa Prentiss,Viral Kansara,Bruce D Jaffee,Thaddeus P. Dryja,Michael Roguska +32 more
TL;DR: A 97-amino-acid peptide of human origin that binds hyaluronan, a major macromolecular component of the eye's vitreous, with therapeutic antibodies and proteins is combined to extend the intravitreal half-life of protein drugs as an alternative to either encapsulation or chemical modifications with polymers.
Patent
Dhfr tunable protein regulation
Vipin Suri,Dexue Sun,Michelle Ols,Heller Scott Francis,Dan Jun Li,Celeste Richardson,Mara Christine Inniss,Jennifer Leah Gori,Benjamin Primack,Abhishek Kulkarni,Brian Dolinski,Tucker Ezell,Michael Schebesta,Storer James,Kutlu G. Elpek +14 more
TL;DR: The present disclosure is related to compositions and methods for the regulated and controlled expression of proteins as mentioned in this paper, and is not related to any specific application of the method described in this paper.
Journal ArticleDOI
Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma
Laura A. Johnson,John Scholler,Takayuki Ohkuri,Akemi Kosaka,Prachi R. Patel,Shannon E. McGettigan,Arben Nace,Pramod Thekkat,Andreas Loew,Taylor J. Chen,Joseph A. Fraietta,Avery D. Posey,Alina C. Boesteanu,Alexandria P. Cogdill,Boris Engels,Reshma Singh,Tucker Ezell,Neeraja Idamakanti,Gabriela Plesa,John T. Seykora,Hideho Okada,Carl H. June,Jennifer Brogdon,Marcela V. Maus +23 more
TL;DR: A Phase I clinical study of CAR T cells transduced with humanized scFv directed to EGFR variant III in patients with glioblastoma is designed and tested for its ability to direct CAR-transduced T cells to kill antigen-bearing targets effectively, and proliferate and secrete cytokines specifically in response to antigen.